Hong Kong Stock Movement
BAO PHARMA-B fell 11.80%. Based on recent key news:
<ol>
<li>
On December 30, BAO PHARMA-B announced plans to implement an H-share full circulation plan and submitted filing materials to the China Securities Regulatory Commission, planning to convert approximately 63.1163 million unlisted shares into H-shares, accounting for about 19.36% of the company's total issued shares. This move may lead to short-term fluctuations in the company's stock price.
</li>
<li>
On December 31, Zhitong Finance reported that since its listing on December 10, BAO PHARMA-B's stock price has surged over 200% in 14 trading days. The recent announcement of the full circulation plan may raise investor concerns about the stock being overvalued, leading to a price correction.
</li>
<li>
On December 30, Economic Information Daily reported that BAO PHARMA-B's full circulation plan has not yet completed the filing procedures with the China Securities Regulatory Commission, and the details of the conversion and listing implementation plan have not been finalized, increasing market uncertainty. The liquidity of Hong Kong stocks has improved, attracting institutional investment.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Innovent Biologics rose 3.28%. Based on recent key news:
<ol>
<li>
On December 30, the Hainan Lecheng Hongyuan Medical Technology Innovation Development Research Institute and other institutions initiated an alliance aimed at building a full-chain platform support system, focusing on innovative devices and innovative drugs. This initiative may enhance Innovent Biologics' market position in the innovative drug sector, driving up its stock price.
</li>
<li>
On December 30, the Third Anhui Province Medical and Health Information Technology Innovation Conference was successfully held in Hefei, emphasizing the promotion of the implementation of medical intelligent products. As a participant in medical innovation, Innovent Biologics may benefit from the overall digital transformation of the industry, boosting market confidence.
</li>
<li>
On December 30, He Qiyang proposed at a seminar on new trends in the silver-haired economy to fill the gaps in the elderly care system through artificial intelligence and longevity medicine. This may provide new market opportunities for Innovent Biologics in related product development, further supporting its stock price increase. Innovation in the medical industry boosts market confidence.
</li>
</ol>
BeiGene rose 2.68%. Based on recent key news:
<ol>
<li>
On January 2, Cell Death Dis reported that inhibiting the TIGIT protein is expected to assist the immune system in targeting cancer cells. This research progress may enhance BeiGene's market competitiveness in the field of immunotherapy, driving up its stock price. Source: Financial Associated Press
</li>
<li>
On December 31, pharmaceutical industry analysis pointed out that although the innovative drug sector performed poorly overall, the CXO sector, closely related to the innovative drug industry chain, performed outstandingly. BeiGene, as one of the related companies, benefits from this trend. Source: Sci-Tech Innovation Board Daily
</li>
<li>
Recently, market attention on the innovative drug sector has increased, especially regarding positive expectations for new drug development and overseas BD transactions, boosting investor confidence and driving up stock prices. Source: Sci-Tech Innovation Board Daily. The pharmaceutical sector shows significant differentiation, with outstanding performance in CXO.
</li>
</ol>
3SBio rose 1.49%. Based on recent key news:
<ol>
<li>
On December 30, 2023, Sanofi's autoimmune pipeline progressed rapidly, with multiple products set to enter the harvest period. The NDA applications for IL-17A monoclonal antibody SSGJ-608 and IL-1β monoclonal antibody SSGJ-613 have been accepted, and several Phase III products are expected to be approved in the future, driving up the stock price. Source: Zhitong Finance
</li>
<li>
On December 31, 2023, the sentiment in the Hong Kong medical health IPO market changed. Despite overall enthusiasm, investors favored companies with strong fundamentals, and Sanofi attracted attention due to its robust R&amp;D pipeline. Source: Zhitong Finance
</li>
<li>
On January 2, 2024, a report from China Merchants International pointed out that the mainland's &#34;14th Five-Year Plan&#34; has set the tone, with the market entering a period of policy verification and profit recovery. Sanofi was listed as one of the key stocks for January, attracting investor attention. Source: Zhitong Finance. The investment enthusiasm in the Hong Kong pharmaceutical sector is high, focusing on fundamentals.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
Kangfang Biotech rose by 0.18%. Based on recent key news:
<ol>
<li>
On December 31, 2023, Kangfang Biotech made significant progress on the global R&amp;D map, with all its drugs advancing to the clinical Phase II stage successfully approved for market launch, demonstrating a high R&amp;D success rate and boosting market confidence. Source: Southern Metropolis Daily
</li>
<li>
On December 30, 2023, Huangpu District provided integrated services for biopharmaceutical companies, helping Kangfang Biotech and others accelerate their R&amp;D processes, enhancing investor confidence in their future development. Source: Nanfang Finance International Communication Center
</li>
<li>
In 2022, Kangfang Biotech reached a $5 billion licensing agreement with the American company Summit, reflecting its improved international negotiation position and further driving up the stock price. Source: Southern Metropolis Daily. The globalization trend in the biopharmaceutical industry is evident, with active capital inflows
</li>
</ol>

02659

BAO PHARMA-B fell 11.80%; Innovent Biologics rose 3.28%, with a transaction volume of HKD 198 million; BeiGene rose 2.68%, with a transaction volume of HKD 99.86 million; 3SBio rose 1.49%, with a transaction volume of HKD 78.43 million; CanSino Biologics rose 0.18%, with a market capitalization of HKD 104.3 billion

Hong Kong Stock Movement: BAO PHARMA-B fell 11.80%, full circulation plan raises concerns about overvaluation and market uncertainty